Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation
M. C. Martínez-Campanario, Marlies Cortés, Alazne Moreno-Lanceta, Lu Han, Chiara Ninfali, Verónica Domínguez, María J. Andrés‐Manzano, Marta Farràs, Anna Esteve‐Codina, Carlos Enrich, Francisco Díaz‐Crespo, Belén Pintado, Joan Carles Escolá‐Gil, Pablo Garcı́a de Frutos, Vicente Andrés, Pedro Melgar‐Lesmes, Antonio Postigo
Abstract
Abstract Accumulation of lipid-laden macrophages within the arterial neointima is a critical step in atherosclerotic plaque formation. Here, we show that reduced levels of the cellular plasticity factor ZEB1 in macrophages increase atherosclerotic plaque formation and the chance of cardiovascular events. Compared to control counterparts ( Zeb1 WT / Apoe KO ), male mice with Zeb1 ablation in their myeloid cells ( Zeb1 ∆M / Apoe KO ) have larger atherosclerotic plaques and higher lipid accumulation in their macrophages due to delayed lipid traffic and deficient cholesterol efflux. Zeb1 ∆M / Apoe KO mice display more pronounced systemic metabolic alterations than Zeb1 WT / Apoe KO mice, with higher serum levels of low-density lipoproteins and inflammatory cytokines and larger ectopic fat deposits. Higher lipid accumulation in Zeb1 ∆M macrophages is reverted by the exogenous expression of Zeb1 through macrophage-targeted nanoparticles. In vivo administration of these nanoparticles reduces atherosclerotic plaque formation in Zeb1 ∆M / Apoe KO mice. Finally, low ZEB1 expression in human endarterectomies is associated with plaque rupture and cardiovascular events. These results set ZEB1 in macrophages as a potential target in the treatment of atherosclerosis.